PL2678037T3 - Rozgałęziony łącznik do koniugatów białko-lek. - Google Patents

Rozgałęziony łącznik do koniugatów białko-lek.

Info

Publication number
PL2678037T3
PL2678037T3 PL12706239T PL12706239T PL2678037T3 PL 2678037 T3 PL2678037 T3 PL 2678037T3 PL 12706239 T PL12706239 T PL 12706239T PL 12706239 T PL12706239 T PL 12706239T PL 2678037 T3 PL2678037 T3 PL 2678037T3
Authority
PL
Poland
Prior art keywords
drug conjugates
protein drug
branched linker
linker
branched
Prior art date
Application number
PL12706239T
Other languages
English (en)
Inventor
Laurent Ducry
Bernhard Stump
Wong, (Wang) Heilam (Harry)
Jin She (Jacky)
Gayle Phillips
Original Assignee
Lonza Ag
Lonza Guangzhou Nansha Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza Ag, Lonza Guangzhou Nansha Ltd filed Critical Lonza Ag
Publication of PL2678037T3 publication Critical patent/PL2678037T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL12706239T 2011-02-25 2012-02-23 Rozgałęziony łącznik do koniugatów białko-lek. PL2678037T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2011071287 2011-02-25
CN2011077863 2011-08-01
CN2011081857 2011-11-07
EP12706239.6A EP2678037B1 (en) 2011-02-25 2012-02-23 Branched linker for protein drug conjugates
PCT/EP2012/053039 WO2012113847A1 (en) 2011-02-25 2012-02-23 Branched linker for protein drug conjugates

Publications (1)

Publication Number Publication Date
PL2678037T3 true PL2678037T3 (pl) 2015-05-29

Family

ID=45771806

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12706239T PL2678037T3 (pl) 2011-02-25 2012-02-23 Rozgałęziony łącznik do koniugatów białko-lek.

Country Status (8)

Country Link
US (2) US10294270B2 (pl)
EP (1) EP2678037B1 (pl)
JP (3) JP5559439B2 (pl)
DK (1) DK2678037T3 (pl)
ES (1) ES2531471T3 (pl)
HK (2) HK1186668A1 (pl)
PL (1) PL2678037T3 (pl)
WO (1) WO2012113847A1 (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2678037T3 (pl) * 2011-02-25 2015-05-29 Lonza Ag Rozgałęziony łącznik do koniugatów białko-lek.
JP2016514157A (ja) 2013-03-14 2016-05-19 アルバニー モレキュラー リサーチ， インコーポレイテッド リガンド−治療薬コンジュゲートおよびケイ素ベースのリンカー
EP3590922A1 (en) 2013-03-15 2020-01-08 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
KR20160015227A (ko) 2013-05-31 2016-02-12 제넨테크, 인크. 항-세포벽 테이코산 항체 및 접합체
KR20160015286A (ko) 2013-05-31 2016-02-12 제넨테크, 인크. 항-세포벽 테이코산 항체 및 접합체
EA201690195A1 (ru) 2013-08-12 2016-05-31 Дженентек, Инк. Конъюгатные соединения антитело-лекарство на основе димера 1-(хлорметил)-2,3-дигидро-1h-бензо[e]индола и способы применения и лечения
WO2015038426A1 (en) 2013-09-13 2015-03-19 Asana Biosciences, Llc Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof
WO2015057699A2 (en) 2013-10-15 2015-04-23 Seattle Genetics, Inc. Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
CN105828840B (zh) 2013-12-16 2020-08-04 基因泰克公司 1-(氯甲基)-2,3-二氢-1H-苯并[e]吲哚二聚体抗体-药物缀合物化合物及使用和治疗方法
CN105899526A (zh) 2013-12-17 2016-08-24 诺华股份有限公司 细胞毒性肽和其缀合物
ES2916722T3 (es) 2013-12-27 2022-07-05 Zymeworks Inc Sistemas de enlace que contienen sulfonamida para conjugados de fármacos
CN106459162A (zh) 2013-12-27 2017-02-22 酵活有限公司 Var2csa‑药物偶联物
CN106573956A (zh) 2014-06-13 2017-04-19 诺华股份有限公司 澳瑞他汀衍生物及其缀合物
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
CN113416229A (zh) 2014-09-17 2021-09-21 酵活有限公司 细胞毒性和抗有丝分裂化合物、及其使用方法
SG11201701342XA (en) * 2014-10-24 2017-03-30 Polytherics Ltd Conjugates and conjugating reagents
EP3215519A1 (en) 2014-11-06 2017-09-13 Novartis AG Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
BR112017011325A2 (pt) 2014-12-03 2020-07-21 Genentech, Inc. ?composto de conjugado anticorpo?antibiótico, composição, método de tratamento de uma infecção, método para matar staph aureus, processo para produzir o conjugado, kit para o tratamento de uma infecção, intermediários antibiótico-ligante e ligante-droga?
MX2017007231A (es) 2014-12-03 2017-11-08 Genentech Inc Conjugados de rifamicina y anticuerpos contra el staphylococcuss aureus y usos de estos.
EP3878861A1 (en) 2015-02-16 2021-09-15 Lonza Ltd. Cl and/or ch1 mutated antibodies for drug conjugation
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
US10233212B2 (en) 2015-11-03 2019-03-19 Industrial Technology Research Institute Compounds, linker-drugs and ligand-drug conjugates
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
CA3006000A1 (en) 2015-12-04 2017-06-08 Seattle Genetics, Inc. Conjugates of quaternized tubulysin compounds
MA43835A (fr) 2016-03-25 2018-11-28 Seattle Genetics Inc Procédé de préparation de lieurs de médicaments pégylés et leurs intermédiaires
JP7043425B2 (ja) 2016-06-06 2022-03-29 ジェネンテック， インコーポレイテッド シルベストロール抗体－薬物コンジュゲート及び使用方法
AU2018237683A1 (en) 2017-03-24 2019-10-31 Seagen Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
AU2019277094A1 (en) * 2018-05-29 2021-01-21 Bristol-Myers Squibb Company Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
ES2154590B1 (es) 1999-05-20 2001-11-01 Lipotec Sa Procedimiento de sintesis de peptidos en fase solida
ES2908458T3 (es) 2005-07-18 2022-04-29 Seagen Inc Conjugados de fármaco-enlazador de beta-glucurónido
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2008053479A1 (en) * 2006-10-30 2008-05-08 Ramot At Tel Aviv University Ltd. Self-immolative polymers
PL2678037T3 (pl) * 2011-02-25 2015-05-29 Lonza Ag Rozgałęziony łącznik do koniugatów białko-lek.

Also Published As

Publication number Publication date
US10294270B2 (en) 2019-05-21
US10214560B2 (en) 2019-02-26
DK2678037T3 (en) 2015-03-09
EP2678037A1 (en) 2014-01-01
JP2014169298A (ja) 2014-09-18
WO2012113847A1 (en) 2012-08-30
ES2531471T3 (es) 2015-03-16
EP2678037B1 (en) 2014-12-03
US20180258136A1 (en) 2018-09-13
JP6169520B2 (ja) 2017-07-26
US20130324706A1 (en) 2013-12-05
JP2016128417A (ja) 2016-07-14
HK1186668A1 (en) 2014-03-21
JP2014507439A (ja) 2014-03-27
JP5559439B2 (ja) 2014-07-23
HK1213773A1 (zh) 2016-07-15

Similar Documents

Publication Publication Date Title
HK1213773A1 (zh) 用於蛋白質藥物偶聯物的支鏈聯接體
IL263973B (en) Protein-polymer-drug conjugates
HK1221153A1 (zh) 抗體-藥物綴合物
HK1208186A1 (en) Drug protein conjugates
HK1208187A1 (en) Drug protein conjugates
HK1210477A1 (en) Antibody drug conjugate
EP2723393A4 (en) EXTRACELLULAR TARGETED CONSTITUENT CONJUGATES
IL236323A0 (en) Drug conjugates of anti–cd70 antibody
HK1196257A1 (zh) -抗體結合物
HK1198298A1 (en) Genes nd proteins for lkanoyl-coa synthesis
HK1189031A1 (zh) 用於細胞內遞送核酸的小分子綴合物
HK1201727A1 (en) Anticancer fusion protein
EP2683737A4 (en) EXTRACELLULAR TARGETED CONSTITUENT CONJUGATES
HK1201848A1 (en) Anticancer fusion protein
EP2575887A4 (en) CONJUGATES OF OPTIMIZED MEDICINES
SG10201604667YA (en) Pharmaceutical preparation
IL226205A0 (en) anticancer fusion protein
GB201105298D0 (en) Pharmaceutical preparation
ZA201308597B (en) Anticancer fusion protein
ZA201304462B (en) Novel conjugates for targeted drug delivery
PL2691119T3 (pl) Preparat farmaceutyczny
HK1203150A1 (en) Improved processes for preparing peptide conjugates and linkers
GB201119796D0 (en) Pharmaceutical comopounds